首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Dose escalation in the radiotherapy of non-small-cell lung cancer with aperture-based intensity modulation and photon beam energy optimization for non-preselected patients.
【24h】

Dose escalation in the radiotherapy of non-small-cell lung cancer with aperture-based intensity modulation and photon beam energy optimization for non-preselected patients.

机译:非小细胞肺癌患者基于孔径的强度调制和光子束能量优化的放疗剂量递增。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To verify the potential of aperture-based intensity-modulated radiotherapy (AB-IMRT) to realize dose escalation plans for non-preselected non-small-cell lung cancer (NSCLC) patients, using photon beam energy optimization. METHODS AND MATERIALS: Seven cases of NSCLC were retrospectively studied. Clinical reference plans were made at 60 Gy by an experienced dosimetrist. Dose escalation was applied to PTV2, a subvolume within the main PTV1. Escalation plans were optimized by considering beam angles (table and gantry), energy (6 and 23 MV) and weights, for an increasing dose to the PTV2, starting from 66 Gy and keeping 30 fractions. RESULTS: In five cases, doses over 78 Gy could be achieved before exceeding organs at risk (OARs) standard tolerance. Peripheral overdosages, as well as lung and spinal cord tolerance doses, limited escalation. Means+/-SD V(95%) parameters were (97.3+/-0.9)% for PTV1s and (96.7+/-2.2)% for PTV2s. Doses to OARs were also maintained at acceptable levels. Optimized plans made use of both low- and high-energy beams and had a similar number of monitor units compared to the 60 Gy clinical plans. CONCLUSIONS: The AB-IMRT system can successfully realize dose escalation for a sizeable number of cases. Plans produced contained few large segments, and are applicable to a wide range of tumor volumes and locations.
机译:目的:利用光子束能量优化技术,验证基于孔径的强度调制放射疗法(AB-IMRT)实现非预选非小细胞肺癌(NSCLC)患者剂量递增计划的潜力。方法与材料:回顾性研究7例非小细胞肺癌。由经验丰富的剂量师在60 Gy时制定临床参考计划。剂量升级已应用于PTV2,这是主PTV1内的一个子卷。通过考虑光束角度(工作台和机架),能量(6和23 MV)和重量来优化升级计划,以增加对PTV2的剂量,从66 Gy开始并保留30个分数。结果:在五种情况下,超过危险器官标准(OARs)的标准耐受性之前,可以达到78 Gy以上的剂量。外周过量,以及肺和脊髓耐受剂量限制了升级。 PTV1的平均值+/- SD V(95%)参数为(97.3 +/- 0.9)%,PTV2的平均值为(96.7 +/- 2.2)%。对OAR的剂量也维持在可接受的水平。与60 Gy临床计划相比,优化计划同时使用了低能量和高能量光束,并且具有相似数量的监测器。结论:AB-IMRT系统可以成功实现大量病例的剂量递增。产生的计划几乎没有大的部分,并且适用于广泛的肿瘤体积和位置。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号